Cyber Swan Sale

50% Off Elite

Days

Hours

Mins

Sec

Get our most powerful screeners, new charting tools, and the fastest ad-free experience at our best price ever. One last chance.

JANX

Janux Therapeutics Inc

Dec 02 • 04:00PM ET

15.86

-18.13 -53.34 %

Healthcare • Biotechnology • USA • NASD

Dec 02, 9:31 AMInterim Phase 1 trial data for JANX007 in prostate cancer disappoints investors despite company's positive framing.

Peers: BMRN BPMC KURA BLUE ALLO ADAP TVRD FATE PTCT AVIR

| Held by: XBI VTI IWM VXF IBB SCHA IWN VTWO IDNA IWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.68	Insider Own	10.56%	Shs Outstand	60.12M	Perf Week	-49.70%
Market Cap	953.94M	Forward P/E	-	EPS next Y	-2.82	Insider Trans	-0.31%	Shs Float	53.79M	Perf Month	-44.76%
Enterprise Value	-12.39M	PEG	-	EPS next Q	-0.63	Inst Own	106.97%	Short Float	13.26%	Perf Quarter	-31.16%
Income	-101.89M	P/S	95.39	EPS this Y	-52.22%	Inst Trans	1.47%	Short Ratio	5.66	Perf Half Y	-37.63%
Sales	10.00M	P/B	0.98	EPS next Y	-44.80%	ROA	-11.85%	Short Interest	7.13M	Perf YTD	-70.38%
Book/sh	16.24	P/C	0.96	EPS next 5Y	-	ROE	-12.48%	52W High	71.71 -77.88%	Perf Year	-65.81%
Cash/sh	16.44	P/FCF	-	EPS past 3/5Y	-17.45% -67.90%	ROIC	-10.22%	52W Low	21.73 -27.01%	Perf 3Y	13.85%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	42.79% -	Gross Margin	79.27%	Volatility	9.42% 7.89%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-1.24	EPS Y/Y TTM	-42.45%	Oper. Margin	-1442.88%	ATR (14)	3.18	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	35.86	Sales Y/Y TTM	-23.37%	Profit Margin	-1018.95%	RSI (14)	27.50	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	35.86	EPS Q/Q	23.68%	SMA20	-45.33%	Beta	2.88	Target Price	64.82
Payout	-	Debt/Eq	0.02	Sales Q/Q	2177.90%	SMA50	-41.06%	Rel Volume	15.49	Prev Close	33.99
Employees	81	LT Debt/Eq	0.02	Earnings	Nov 06 AMC	SMA200	-40.72%	Avg Volume	1.26M	Price	15.86
IPO	Jun 11, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.33% 248.83%	Trades		Volume	15,978,016	Change	-53.34%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-17-25	Initiated	Barclays	Overweight	$47
Sep-10-25	Initiated	Truist	Buy	$100
Sep-10-25	Initiated	Stifel	Buy	$45
Sep-04-25	Initiated	Guggenheim	Buy	$72
Aug-19-25	Initiated	Piper Sandler	Overweight	$42
Jul-11-25	Initiated	Raymond James	Outperform	$65
Dec-03-24	Reiterated	H.C. Wainwright	Buy	$63 → $70
Dec-03-24	Reiterated	BTIG Research	Buy	$82 → $100
Nov-22-24	Initiated	Leerink Partners	Outperform	$79
Oct-24-24	Initiated	UBS	Buy	$69
Sep-06-24	Initiated	Stifel	Buy	$70
May-30-24	Initiated	Scotiabank	Sector Perform	$47
Mar-21-24	Initiated	BTIG Research	Buy	$62
Mar-20-24	Initiated	Cantor Fitzgerald	Overweight	$100
Apr-06-23	Initiated	Wedbush	Outperform	$24
Nov-14-22	Initiated	William Blair	Outperform

Show Previous Ratings

Dec-02-25 10:14AM	Janux Therapeutics Craters 50% On Prostate Cancer Update; Is It An 'Overreaction'? (Investor's Business Daily) -53.34%
09:53AM	Janux Therapeutics Stock Craters After Positive Cancer Data. Why Its Down 50%. (Barrons.com)
08:30AM	Janux Therapeutics Stock Craters After 'Positive' Cancer Drug Trial Data. Why It's Down 41%. (Barrons.com)
05:15AM	Janux sinks on overreaction to prostate cancer data; RFK Jr. replaces ACIP chair (BioPharma Dive)
Dec-01-25 04:05PM	Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC (Business Wire)
08:00AM	Loading…
Nov-24-25 08:00AM	Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC (Business Wire) +9.48%
Nov-16-25 10:13PM	Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program (Insider Monkey)
Nov-06-25 06:10PM	Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.61%
04:01PM	Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights (Business Wire)
Oct-30-25 05:53AM	Wave Life Sciences (WVE) Soars 8.8%: Is Further Upside Left in the Stock? (Zacks)
Oct-29-25 07:46AM	Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last? (Zacks) -6.55%
07:05AM	GSK (GSK) Q3 Earnings and Revenues Beat Estimates (Zacks)
Oct-20-25 11:08PM	Janux Therapeutics (JANX) Gets Initiated With a Buy Rating at Truist Financial (Insider Monkey)
Oct-10-25 10:06AM	Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? (Zacks)
Oct-09-25 09:25AM	Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? (Zacks) +6.82%
09:09AM	Loading…
Sep-15-25 09:09AM	Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT (Insider Monkey)
Sep-10-25 09:51AM	Synopsys downgraded, Oracle upgraded: Wall Street's top analyst calls (The Fly)
Aug-17-25 11:41PM	Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration (Insider Monkey)
Aug-07-25 04:01PM	Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire) -6.62%
Aug-05-25 04:05PM	Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck (Business Wire) +6.65% -5.18%
Jul-24-25 04:05PM	Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day (Business Wire)
Jul-17-25 04:30PM	Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 (Business Wire)
Jul-12-25 09:40AM	CoreWeave initiated, Texas Instruments upgraded: Wall Streets top analyst calls (TipRanks)
Jul-11-25 09:38AM	CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls (The Fly)
Jun-24-25 05:42PM	JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target (Insider Monkey)
May-15-25 08:00AM	Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer (Business Wire)
May-08-25 04:01PM	Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-06-25 05:30AM	Janux commences Phase Ib studies in trial for prostate cancer treatment (Clinical Trials Arena) -14.27%
May-05-25 10:10AM	Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross' Stock Picks with Huge Upside Potential (Insider Monkey) -9.40%
08:30AM	Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates (Business Wire)
07:58AM	Loading…
07:58AM	Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? (Insider Monkey)
Apr-07-25 05:14PM	Janux Therapeutics: What's My Inflection Point? (Seeking Alpha) -5.39%
Apr-05-25 08:14AM	Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout (Seeking Alpha)
Mar-28-25 10:36AM	Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? (Insider Monkey)
Mar-26-25 09:40PM	Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
Mar-25-25 10:45AM	Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
Mar-20-25 04:43PM	Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-14-25 06:17PM	WEX, Lamb Weston, and More Stocks See Action From Activist Investors (Barrons.com)
12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-05-25 06:53PM	Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently (Insider Monkey) +5.04%
Mar-01-25 10:00AM	Janux Therapeutics price target lowered to $41 from $62 at Scotiabank (TipRanks)
Feb-27-25 04:01PM	Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire)
Feb-24-25 01:07PM	Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now (Insider Monkey) -6.75%
Jan-24-25 04:01PM	Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer (Business Wire)
Dec-06-24 07:43PM	Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million (Business Wire) -5.14%
Dec-04-24 11:12PM	Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) +11.65%
06:23PM	Why Janux Therapeutics Crushed the Market Today (Motley Fool)
Dec-03-24 04:07PM	Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride (Investor's Business Daily) +48.98%
04:01PM	Janux Therapeutics Announces Proposed Public Offering (Business Wire)
11:58AM	Janux Rockets 41% in Five Days as Cancer Breakthrough Fuels Market Buzz (GuruFocus.com)
11:20AM	Janux Therapeutics Stock Soars on Prostate Cancer Drug Trial Results (Barrons.com)
10:01AM	Janux Skyrockets: 69% Surge This Morning Leads to 650% Gain in a Year (GuruFocus.com)
09:02AM	Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients (Investor's Business Daily)
06:13AM	Janux impresses Wall Street with new prostate cancer drug results (BioPharma Dive)
Dec-02-24 04:30PM	Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC (Business Wire) -11.13%
Nov-25-24 09:00AM	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies (Business Wire)
Nov-23-24 06:21AM	Janux Therapeutics initiated with an Outperform at Leerink (TipRanks)
Nov-15-24 08:34PM	Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-06-24 04:01PM	Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
Nov-01-24 06:33PM	Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-23-24 09:05PM	Paradigm Biocapital Advisors LP Acquires Shares in Janux Therapeutics Inc (GuruFocus.com)
Oct-22-24 09:07PM	RA Capital Management Reduces Stake in Janux Therapeutics (GuruFocus.com)
Oct-07-24 05:08PM	Janux Therapeutics, Inc. (JANX): A Hot Stock to Buy Now (Insider Monkey)
Sep-26-24 07:30PM	Is Janux Therapeutics Inc. (JANX) the Best Performing Small-Cap Stock in 2024? (Insider Monkey)
Sep-20-24 06:39PM	Lennar, Bitdeer, and More Stocks See Action From Activist Investors (Barrons.com)
Sep-17-24 01:30AM	RA Capital Management L.P. Increases Stake in Janux Therapeutics Inc (GuruFocus.com)
Sep-14-24 07:33PM	Janux Therapeutics, Inc. (JANX): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-13-24 06:10AM	Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last? (Zacks) +7.48%
Aug-16-24 04:36PM	Southwest Airlines, Rocket Lab USA, and More Stocks See Action From Activist Investors (Barrons.com) +5.08%
Aug-07-24 11:54PM	JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:15PM	Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
Jul-22-24 04:01PM	Janux Therapeutics Announces Updates to Board of Directors (Business Wire) +6.80%
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
Jun-14-24 07:05PM	TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors (Barrons.com)
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
May-09-24 10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire) -6.19%
May-08-24 09:06AM	Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating (MT Newswires) -9.97%
07:32AM	Janux Therapeutics Reports Narrower Q1 Loss, Misses Revenue Estimates (GuruFocus.com)
May-07-24 10:56PM	JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:01PM	Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
Apr-30-24 08:50AM	Here's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price Strength (Zacks)
Apr-25-24 11:28AM	11 Oversold MidCap Stocks To Buy Now (Insider Monkey)
Apr-17-24 01:12PM	Take the Money and Run: 3 Overbought Stocks to Sell ASAP (InvestorPlace) -5.12%
Apr-16-24 01:19PM	These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come? (InvestorPlace)
Apr-15-24 12:54PM	Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors (Zacks)
Apr-12-24 08:50AM	Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +5.30%
05:40AM	Why Janux Therapeutics Stock Is Crushing It This Week (Motley Fool)
Apr-11-24 04:19PM	Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily) +12.06%
02:13PM	Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday? (Benzinga)
09:55AM	Wall Street Analysts Think Janux Therapeutics (JANX) Could Surge 40.3%: Read This Before Placing a Bet (Zacks)
09:17AM	Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
Apr-10-24 06:39PM	Why Janux Therapeutics Stock Soared as the Market Sagged Today (Motley Fool) +11.47%
Apr-08-24 09:35AM	After Plunging -11.78% in 4 Weeks, Here's Why the Trend Might Reverse for Janux Therapeutics (JANX) (Zacks) +9.99%
Mar-28-24 12:00PM	Janux Therapeutics (JANX) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-22-24 09:55AM	Wall Street Analysts Believe Janux Therapeutics (JANX) Could Rally 57.47%: Here's is How to Trade (Zacks)
Mar-20-24 03:44PM	Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst (Benzinga)
Mar-15-24 10:53AM	JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
09:45AM	2 Stocks That Have More Than Tripled This Year: Are They Buys? (Motley Fool)

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BYRON C ROBINSON	Officer	Dec 02 '25	Proposed Sale	16.38	63,125	1,033,743		Dec 02 05:15 PM
ANDREW MEYER	Officer	Dec 01 '25	Proposed Sale	34.09	3,333	113,622		Dec 01 04:20 PM
Meyer Andrew Hollman	Chief Business Officer	Nov 14 '25	Option Exercise	10.59	3,333	35,296	88,307	Nov 14 08:00 PM
Meyer Andrew Hollman	Chief Business Officer	Nov 14 '25	Sale	30.00	3,333	99,990	84,974	Nov 14 08:00 PM
ANDREW MEYER	Officer	Nov 14 '25	Proposed Sale	27.46	3,333	91,524		Nov 14 04:24 PM
Meyer Andrew Hollman	Chief Business Officer	Oct 28 '25	Option Exercise	6.76	16,665	112,689	98,804	Oct 30 08:00 PM
Meyer Andrew Hollman	Chief Business Officer	Oct 28 '25	Sale	30.06	16,665	500,987	82,139	Oct 30 08:00 PM
ANDREW MEYER	Officer	Oct 28 '25	Proposed Sale	27.35	16,665	455,788		Oct 28 04:16 PM
Meyer Andrew Hollman	Chief Business Officer	May 01 '25	Option Exercise	4.21	3,333	14,032	85,472	May 02 08:00 PM
Meyer Andrew Hollman	Chief Business Officer	May 01 '25	Sale	32.03	3,333	106,745	82,139	May 02 08:00 PM
ANDREW MEYER	Officer	May 01 '25	Proposed Sale	33.20	3,333	110,656		May 01 04:31 PM
Meyer Andrew Hollman	Chief Business Officer	Apr 21 '25	Option Exercise	4.21	3,334	14,036	85,473	Apr 23 08:00 PM
Meyer Andrew Hollman	Chief Business Officer	Apr 21 '25	Sale	30.00	3,334	100,020	82,139	Apr 23 08:00 PM
ANDREW MEYER	Officer	Apr 21 '25	Proposed Sale	29.69	3,334	98,986		Apr 21 04:18 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 06 '25	Buy	30.78	372,093	11,453,023	10,031,081	Mar 07 06:05 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 05 '25	Buy	30.64	341,742	10,471,352	9,658,988	Mar 07 06:05 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Mar 07 '25	Buy	31.02	110,206	3,418,590	10,141,287	Mar 07 06:05 PM
Meyer Andrew Hollman	Chief Business Officer	Mar 03 '25	Option Exercise	4.21	3,334	14,036	85,473	Mar 05 08:00 PM
Meyer Andrew Hollman	Chief Business Officer	Mar 03 '25	Sale	32.15	3,334	107,174	82,139	Mar 05 08:00 PM
ANDREW MEYER	Officer	Mar 03 '25	Proposed Sale	32.89	3,334	109,655		Mar 03 04:25 PM
Meyer Andrew Hollman	Chief Business Officer	Feb 03 '25	Option Exercise	4.21	3,334	14,036	85,473	Feb 05 08:00 PM
Meyer Andrew Hollman	Chief Business Officer	Feb 03 '25	Sale	42.29	3,334	140,999	82,139	Feb 05 08:00 PM
ANDREW MEYER	Officer	Feb 03 '25	Proposed Sale	43.48	3,334	144,962		Feb 03 04:18 PM
Campbell David Alan	President and CEO	Jan 07 '25	Sale	60.00	5,000	300,004	293,054	Jan 08 08:00 PM
Campbell David Alan	Officer	Jan 07 '25	Proposed Sale	60.00	5,000	300,004		Jan 07 04:11 PM
Meyer Andrew Hollman	Chief Business Officer	Jan 02 '25	Sale	54.88	13,334	731,785	82,139	Jan 03 05:10 PM
ANDREW MEYER	Officer	Jan 02 '25	Proposed Sale	53.54	13,334	713,902		Jan 02 04:24 PM
Campbell David Alan	President and CEO	Dec 24 '24	Sale	56.19	25,000	1,404,805	217,054	Dec 27 08:00 PM
Campbell David Alan	Officer	Dec 26 '24	Proposed Sale	56.19	25,000	1,404,805		Dec 26 10:00 AM
Meyer Andrew Hollman	Chief Business Officer	Dec 19 '24	Option Exercise	20.24	9,881	199,985	77,473	Dec 20 06:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Cyber Swan Sale

50% Off Elite

JANX

Janux Therapeutics Inc

Upgrade your FINVIZ experience